Defining the Prevalence and Incidence of Androgen Deficiency in Aging Men: Where Are the Goal Posts?
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The physical and cognitive declines noted by men as they age have historically been regarded as an integral part of the normal aging process, yet have also long been the target of empirical therapies aimed at restoring youthful vigor. In recent years, there has been a great deal of medical, social, and commercial interest in whether a decline in serum testosterone (T) underscores some of these changes and would thus be amenable to T replacement therapy (TRT). Various terms have been popularized such as “andropause” or “partial androgen deficiency of the aging male,” yet there is no consensus on their definitions (1, 2). It is clear that total T levels decline by 1–2% per annum beginning at ages in the fourth decade, and consequently an increasing proportion of the aging male population has serum T levels below the reference range for healthy young men. For example, age-stratified prevalence data from the Baltimore Longitudinal Study of Aging showed that 19% of 60- to 69-yr-old men had total T levels below those of normal young men (3), raising the possibility that large numbers of men, simply by virtue of falling below an arbitrary threshold, are potential candidates for TRT. However, the nonspecific symptoms consistent with, but not diagnostic of, androgen deficiency (AD) that are prevalent in aging men may be partially or wholly due to comorbidities (4). Despite lack of evidence of benefit over risk (1), clinical practice has evolved rapidly in this area, fuelled by patient expectations of improved physical function and quality of life and by the availability of convenient forms of T (such as the hydroalcoholic gels), leading to a 29% increase in the prescription of TRT between the years 2001 and 2002 (1), mainly in 46- to 65-yr-old men. The diagnosis of AD demands a synthesis of both clinical features and serum T measures particularly in aging men, as neither is consistently reliable in isolation. With unambiguous clinical features in men with established testicular or pituitary pathology and a serum T level less than 200–250 ng/dl (6.9–8.7 nm), the diagnosis of AD and the merits of treatment are well grounded. In clinical practice, however, most men present with relatively nonspecific symptoms, have confounding medical diagnoses (obesity, chronic illness), and maintain serum T levels in the low-normal range. Moreover, biochemical evaluation is complicated by interindividual variability in normal serum T (extending over a 4-fold range), poor assay performance characteristics, and inappropriate reference ranges (see below). Although attractive and certainly convenient, use of single-value cut-offs to decide clinical treatment is best described as “endonumerology!” The article by Araujo et al. (5) in this issue, for the first time, attempts to estimate the prevalence and incidence of AD in a prospective longitudinal study using operational diagnostic criteria based on clinical and biochemical parameters, reflecting the recommendation of the Second Annual Andropause Consensus group (2). The Massachusetts Male Aging Study (MMAS) data set includes eight of the 12 clinical features proposed by the consensus group, along with serum total T (determined by a robust assay method) and calculated free T values. Their data are a considerable advance on prior studies reporting biochemical thresholds alone and provide a prototype for developing a more rational algorithm for the diagnosis of AD and for identifying cohorts for interventional clinical research studies. However, the authors readily acknowledge that their data have limitations, particularly in regard to the definition of AD. For example, subjects needed three or more positive responses to the eight questions for the diagnosis of AD. Most of these variables were assessed on a 1–4 scale, but the thresholds for these subscales are not provided other than for lethargy and erectile dysfunction. For lethargy, if a subject answered “some or a little” to the question “I could not get going” (in the past week), a positive response was recorded, yet many eugonadal men could be expected to respond in this way. For libido, a response that sexual activity was considered only once daily was recorded as a positive symptom of AD. The authors acknowledge that their choice of the three positive responses threshold was arbitrary, stating that two would not have been enough and eight would have been unreasonably stringent. Herein lies the problem with symptom questionnaires: symptoms and signs suggestive of AD are nonspecific and readily accounted for by comorbidities. Lethargy, reduced concentration, sleep disturbance, irritability, and depressed mood may relate to physical illness (and side effects of treatment), obesity, and/or lack of physical exercise and other lifestyle issues (such as alcohol or drug abuse), relationship difficulties, and occupational or financial stresses. Even low libido, a classic feature of AD, is commonly related to such comorbidities. Finally, ere
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men
Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J., & Blackman, M. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7219 · Cited by 2,760 · cited 1×
“For example, agestratified prevalence data from the Baltimore Longitudinal Study of Aging showed that 19% of 60- to 69-yr-old men had total T levels below those of normal young men (3), raising the possibility that large numbers of men, simply by virtue of falling below an arbitrary threshold, are potential candidates…”
BackgroundFeldman, H. A., Longcope, C., Derby, C. A., Johannes, C. B., Araujo, A. B., Coviello, A. D., Bremner, W. J., & McKinlay, J. B. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8201 · Cited by 1,861
Araujo, A. B., O’Donnell, A. B., Brambilla, D. J., Simpson, W. B., Longcope, C., Matsumoto, A. M., & McKinlay, J. B. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031719 · Cited by 591 · cited 1×
“(5) in this issue, for the first time,”
BackgroundWang, C., Catlin, D. H., Demers, L. M., Starcevic, B., & Swerdloff, R. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031287 · Cited by 580 · cited 2×
“The performance of commercial assay platforms has recently been evaluated against a quantitative mass spectroscopy method and all showed substantial biases that varied between platforms and across the working range, especially at the lower end of greatest importance to diagnosis of AD (15, 16).”
MethodModifiable risk factors and erectile dysfunction: can lifestyle changes modify risk?
Derby, C. A., Mohr, B. A., Goldstein, I., Feldman, H. A., Johannes, C. B., & McKinlay, J. B. (2000) · Urology · doi:10.1016/s0090-4295(00)00614-2 · Cited by 552
Low serum testosterone and sex-hormone-binding-globulin in massively obese men
GLASS, A. R., SWERDLOFF, R. S., BRAY, G. A., DAHMS, W. T., & ATKINSON, R. L. (1977) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-45-6-1211 · Cited by 430 · cited 4×
“00/0 The Journal of Clinical Endocrinology & Metabolism 89(12):5916–5919”
BackgroundInfluentialField, A. E., Colditz, G. A., Willett, W. C., Longcope, C., & McKinlay, J. B. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.79.5.7962322 · Cited by 421 · cited 1×
“Their previously published data have shown that comorbidities themselves suppress serum T levels (9, 10) and so the apparent hypoandrogenemia may simply reflect their severity and point to the need to address these problems rather than triggering the use of TRT.”
BackgroundEvaluation of assays available to measure free testosterone
Morley, J. E., Patrick, P., & Perry, H. M. (2002) · Metabolism · doi:10.1053/meta.2002.31975 · Cited by 309
Leifke, E., Gorenoi, V., Wichers, C., Von Zur Mühlen, A., Von Büren, E., & Brabant, G. (2000) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2000.01159.x · Cited by 262 · cited 1×
“If the latter elite group are doing so well with a median total T levels of around 14 nm (400 ng/dl) (as reported for healthy nonobese 60 yr olds) (18), why should one aspire to take a group of symptomatic men and move them to 20 nm (580 ng/d) range? At some point, the use of exogenous T in aging men with borderline n…”
Background
Cited by
Prevalence of hypogonadism in males aged at least 45 years: the HIM study
MULLIGAN, T., FRICK, M. F., ZURAW, Q. C., STEMHAGEN, A., & MCWHIRTER, C. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.00992.x · Cited by 767
Andersen, M. L., & Tufik, S. (2008) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2007.12.003 · Cited by 118
Association Between Sleep and Morning Testosterone Levels In Older Men
Penev, P. D. (2007) · Sleep · doi:10.1093/sleep/30.4.427 · Cited by 86
Metadata
- Authors
- McLachlan, R. I., & Allan, C. A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2004-12
- Volume
- 89
- Issue
- 12
- Pages
- 5916-5919
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2016664718
- Cited by
- 37
- References
- 9
- FWCI
- 2.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Defining the Prevalence and Incidence of Androgen Deficiency in Aging Men: Where Are the Goal Posts? https://app.cochat.ai/papers/10.1210/jc.2004-2035
- The paper
- McLachlan, R. I., & Allan, C. A. (2004). Defining the Prevalence and Incidence of Androgen Deficiency in Aging Men: Where Are the Goal Posts? The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2004-2035
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.